公开(公告)号：US11814431B2

公开(公告)日：2023-11-14

申请号：US16814627

申请日：2020-03-10

申请人： Five Prime Therapeutics, Inc.

发明人： Charles Kaplan ,  Derrick Houser ,  Luis Borges ,  Gloria Brattich ,  David Bellovin ,  Felicia Kemp ,  Majid Ghoddusi ,  Nels P. Nielson ,  Kathy Miller ,  Maike Schmidt

IPC分类号： C07K16/28 ,  A61K39/395 ,  G01N33/53 ,  A61P35/00 ,  G01N33/574 ,  A61K39/00

CPC分类号： C07K16/2827 ,  A61P35/00 ,  C07K16/2818 ,  G01N33/57492 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

摘要： The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

公开(公告)号：US11306144B2

公开(公告)日：2022-04-19

申请号：US16111064

申请日：2018-08-23

申请人： Five Prime Therapeutics, Inc.

发明人： Charles Kaplan ,  Derrick Houser ,  Luis Borges ,  Gloria Brattich ,  David Bellovin ,  Felicia Kemp ,  Majid Ghoddusi ,  Nels P. Nielson ,  Kathy Miller ,  Maike Schmidt

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  G01N33/574 ,  A61K39/00

摘要： The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

公开(公告)号：US20240043542A1

公开(公告)日：2024-02-08

申请号：US18484986

申请日：2023-10-11

申请人： FIVE PRIME THERAPEUTICS, INC.

发明人： Charles Kaplan ,  Derrick Houser ,  Luis Borges ,  Gloria Brattich ,  David Bellovin ,  Felicia Kemp ,  Majid Ghoddusi ,  Nels P. Nielson ,  Kathy Miller ,  Maike Schmidt

IPC分类号： C07K16/28 ,  A61P35/00 ,  G01N33/574

CPC分类号： C07K16/2827 ,  C07K16/2818 ,  A61P35/00 ,  G01N33/57492 ,  A61K2039/505

摘要： The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

公开(公告)号：US20230013293A1

公开(公告)日：2023-01-19

申请号：US17685056

申请日：2022-03-02

申请人： FIVE PRIME THERAPEUTICS, INC.

发明人： Charles Kaplan ,  Derrick Houser ,  Luis Borges ,  Gloria Brattich ,  David Bellovin ,  Felicia Kemp ,  Majid Ghoddusi ,  Nels P. Nielson ,  Kathy Miller ,  Maike Schmidt

IPC分类号： C07K16/28 ,  A61P35/00 ,  G01N33/574

摘要： The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

公开(公告)号：US20190085080A1

公开(公告)日：2019-03-21

申请号：US16111064

申请日：2018-08-23

申请人： Five Prime Therapeutics, Inc.

发明人： Charles Kaplan ,  Derrick Houser ,  Luis Borges ,  Gloria Brattich ,  David Bellovin ,  Felicia Kemp ,  Majid Ghoddusi ,  Nels P. Nielson ,  Kathy Miller ,  Maike Schmidt

IPC分类号： C07K16/28 ,  A61P35/00 ,  G01N33/574

摘要： The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.